Form 4: Xencor Director Todd Simpson Receives Significant Equity Grant

Xencor Inc. Director Todd E. Simpson was granted 13,686 restricted stock units and options to purchase 27,372 shares of common stock, aligning his interests with shareholders.

Summary

• Todd E. Simpson, a Director of Xencor Inc. (XNCR), reported the acquisition of equity securities.
• On June 12, 2025, Mr. Simpson was granted 13,686 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were acquired at a price of $0 and are set to fully vest on the first anniversary of the grant date, which is June 12, 2026.
• Additionally, on June 12, 2025, Mr. Simpson was granted stock options to acquire 27,372 shares of Common Stock.
• The exercise price for these stock options is $9.43 per share.
• The stock options will vest in equal monthly installments over one year, beginning one month after the grant date, with full vesting by June 12, 2026.
• The expiration date for these stock options is June 11, 2035.
• Following these transactions, Mr. Simpson beneficially owns 13,686 shares of Common Stock directly and 27,372 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant new company developments.

Positives

• The equity grants to Director Todd E. Simpson align his financial interests directly with those of Xencor Inc. shareholders, promoting long-term value creation.
• The vesting schedules for both the Restricted Stock Units (RSUs) and stock options encourage continued commitment and performance from the director over a one-year period.

Future Outlook

The document does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, focusing solely on an insider's equity transactions.

Industry Context

Equity grants, including Restricted Stock Units and stock options, are a standard component of director and executive compensation packages across the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and align the interests of leadership with those of shareholders, reflecting a common practice in high-growth, research-intensive sectors like biotech.

Comparison to Industry Standards

• The structure of equity compensation, involving both Restricted Stock Units (RSUs) and stock options with multi-year vesting, is a common practice for director compensation in the biotechnology sector, similar to companies like Amgen Inc. or Gilead Sciences, Inc., which frequently use such instruments to retain talent and align interests.
• The grant of RSUs at a $0 price is typical for compensation, representing a direct award of shares subject to vesting conditions.
• The exercise price of $9.43 for the stock options is based on the market price at the time of grant, which is standard for 'at-the-money' options designed to provide value as the stock price appreciates.

Related Party Transactions

• The document details an equity grant from Xencor Inc. to Todd E. Simpson, a Director of the company. This constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the director's long-term interests with shareholder value creation, potentially leading to more focused governance and strategic decisions.
• Employees: While not directly impacted, the compensation structure for directors can set a precedent or reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The Restricted Stock Units (RSUs) are expected to fully vest on June 12, 2026.
• The stock options will continue to vest in equal monthly installments until fully vested on June 12, 2026.

Key Dates

Keywords

Xencor, XNCR, Form 4, Insider Trading, Equity Grant, Stock Options, Restricted Stock Units, Director Compensation, Executive Compensation, Biotechnology